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ABSTRACT
Role of Epistasis in Alzheimer’s Disease Genetics
Mark T. W. Ebbert
Department of Biology, BYU
Doctor of Philosophy
Alzheimer’s disease is a complex neurodegenerative disease whose basic etiology and
genetic structure remains elusive, despite decades of intensive investigation. To date, the
significant genetic markers identified have no obvious functional effects, and are unlikely to play
a role in Alzheimer’s disease etiology, themselves. These markers are likely linked to other
genetic variations, rare or common. Regardless of what causal mutations are found, research has
demonstrated that no single gene determines Alzheimer’s disease development and progression.
It is clear that Alzheimer’s disease development and progression are based on a set of
interactions between genes and environmental variables. This dissertation focuses on gene-gene
interactions (epistasis) and their effects on Alzheimer’s disease case-control status.
We genotyped the top Alzheimer’s disease genetic markers as found on AlzGene.org
(accessed 2014), and tested for interactions that were associated with Alzheimer’s disease casecontrol status. We identified two potential gene-gene interactions between rs11136000 (CLU)
and rs670139 (MS4A4E) (synergy factor = 3.81; p = 0.016), and rs3865444 (CD33) and
rs670139 (MS4A4E) (synergy factor = 5.31; p = 0.003). Based on one data set alone, however, it
is difficult to know whether the interactions are real. We replicated the CLU-MS4A4E interaction
in an independent data set from the Alzheimer’s Disease Genetics Consortium (synergy factor =
2.37, p = 0.007) using a meta-analysis. We also identified potential dosage (synergy factor = 2.98, p
= 0.05) and APOE ε4 effects (synergy factor = 4.75, p = 0.005) in Cache County that did not replicate
independently. The APOE ε4 effect is an association with Alzheimer’s disease case-control status in
APOE ε4 negative individuals. There is minor evidence both the dosage (synergy factor = 1.73, p = 0.02)
and APOE ε4 (synergy factor = 2.08, p = 0.004) effects are real, however, because they replicate when
including the Cache County data in the meta-analysis. These results demonstrate the importance of
understanding the role of epistasis in Alzheimer’s disease.

During this research, we also developed a novel tool known as the Variant Tool Chest.
The Variant Tool Chest has played an integral part in this research and other projects, and was
developed to fill numerous gaps in next-generation sequence data analysis. Critical features
include advanced, genotype-aware set operations on single- or multi-sample variant call format
(VCF) files. These features are critical for genetics studies using next-generation sequencing
data, and were used to perform important analyses in the third study of this dissertation.
By understanding the role of epistasis in Alzheimer’s disease, researchers will begin to
untangle the complex nature of Alzheimer’s disease etiology. With this information, therapies
and diagnostics will be possible, alleviating millions of patients, their families and caregivers of
the painful experience Alzheimer’s disease inflicts upon them.
Keywords: Alzheimer’s disease, epistasis, MS4A4E, CLU, CD33
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Chapter 1
Background
Epistasis involves multiple genes contributing to a single phenotype, but understanding
the nature of an epistatic interaction is not always clear. Epistatic interactions are generally
discovered in two ways: (1) statistically; and (2) biologically. Statistical epistasis is deviation
from additive effects between factors in the model1 , while biological epistasis is a physical
interaction between two or more biological components. Both statistical and biological epistasis
affect a single phenotype, however.
Bridging the gap between statistical and biological epistasis is a challenging, but
necessary task for understanding genetics at its roots. Most phenotypes involve epistasis in
complex organisms. Experiments to discover biological epistasis are challenging to carry out and
limited in the interactions that they can identify. Identifying statistical epistasis also results in
unique challenges. Specifically, discovering that two biological molecules interact provides
crucial pathway and functional information, but the implications across phenotypes are often less
obvious. Furthermore, just because proteins from two genes don’t physically interact does not
mean they do not both affect the same phenotype; the two proteins may be involved in the same
pathway and cause different cascading events, or a given phenotype may be determined by
multiple pathways. The possibilities seem endless. This limitation of understanding biological
epistasis is where statistical epistasis excels. Using statistics, we can explore whether multiple
genetic factors have a non-additive effect on a phenotype. If so, these genetic factors may be coinvolved in the phenotype’s presentation. Limitations of statistically derived epistasis, however,
involve a certain level of uncertainty in the results because of: (1) false-positive and falsenegative results; and (2) biological uncertainty. False-positive results are rampant when testing
1

numerous hypotheses, while false-negatives are likely because of poor statistical power.
Regarding biological uncertainty, any statistically positive result may leave researchers
questioning whether the interaction is real because the biology may not be obvious. In some
cases, little or no information is available about a given gene. By focusing efforts to bridge the
gap between statistical and biological epistasis, researchers will be able to leverage the
complementary strengths of these two approaches and understand genetics at is roots.
Methods to Identify Statistical Epistasis: Merits and Limitations
Identifying statistical epistasis is the most common and cost-effective approach to
discovering gene-gene interactions, but most studies of genetics in human disease focus on single
genetic loci—likely an oversimplification of the underlying biology. To advance our genetic
understanding of all phenotypes, we must understand the underlying epistatic relationships.
Some analysis methods have been developed specifically to identify gene-gene interactions.
Multifactor dimensionality reduction2–17 and logistic regression18–30 are the two most common
methods. Synergy factors are an extension of logistic regression, and for the purposes of this
discussion are included in that group. Multifactor dimensionality reduction is a nonparametric
approach while logistic regression is parametric. Each method has disadvantages that limit their
ability to identify interactions.
Logistic regression has several drawbacks when detecting epistasis according to He et
al15: (1) interaction terms grow exponentially as the number of main effects included in the
model increase; and (2) parameter estimates have large standard errors because the data is highdimensional—decreasing power to detect the interactions. Another limitation according to
Combarros et al. is that logistic regression is generally only valid for binary interactions because
of limited sample size31. Park et al. proposed penalized logistic regression as a method to
2

overcome the limitations and showed that penalized logistic regression performs better than
multifactor dimensionality reduction in some situations32.
Many studies have demonstrated the utility of multifactor dimensionality reduction33–37.
Advantages of multifactor dimensionality reduction include increased power15,38 and superior
ability to identify high-order interactions even when main effects are statistically insignificant32.
Limitations, however, are that it is incapable of identifying additive main effects32 and it
struggles with missing values in high-dimensional data39.
Given that the strengths and limitations of logistic regression and multifactor
dimensionality reduction complement each other, combining them may be a powerful option.
Multifactor dimensionality reduction could be used to discover complex interactions while
logistic regression can be used for main effects.
There are other issues to consider that apply to all available methods such as potential
false positives. According to Page et al.40, there are four reasons an allele or interaction between
alleles can be associated with a complex disease: (1) it is actually causative; (2) the association is
by random chance; (3) a single allele is in disequilibrium with the causative allele; and (4) the
association is due to a systematic bias in some portion of the study. Because of the highdimensionality and small sample size of many studies, there is an increased likelihood of false
positives for reasons stated by Page et al.; however, there is another potential cause of false
positives known as “overfitting”. Overfitting happens when a complex model is fit to data and is
not generalizable beyond the population from which the sample was derived41. The cause has
commonly been attributed to either genetic and environmental heterogeneity42 or due to
epistasis1,43.

3

There are many approaches designed to prevent false positives and overfitting when
studying predictive alleles in a given disease, but they are not fool proof. For instance, protocol
when performing multiple comparisons—thousands in the case of Genome Wide Association
Studies (GWAS)—involves adjusting p-values to limit the number of false positives due to
chance. Similar methods exist to prevent overfitting statistical models to data. Although these
methods are useful, researchers mistakenly report false associations.
Even though weak associations are often reported, this practice is not completely wrong.
Statistical analyses are limited by the available data, and data is limited because of external
restraints such as financial support, limited patient availability, genetic material, and even ethical
restrictions. Given the various challenges researchers face to produce data, it is no wonder weak
associations are reported. The key to separating true and false associations will be testing in
independent data sets if they are large enough, or using meta-analyses across many smaller data
sets to determine if the signal is consistent and significant. If a signal is replicable, researchers
will then need to test associations biologically in cell lines or model organisms.
Epistasis in LOAD
Numerous studies have identified statistical epistasis in Alzheimer’s disease using
logistic regression18–30 and multifactor dimensionality reduction2–14. Here we describe studies
where results have been replicated in at least two independent samples. .
In 2004 Robson et al. identified statistical epistasis between the transferrin (TF) C2 allele
and the haemochromatosis (HFE) C282Y allele using logistic regression and synergy factor
analysis21. These genes were targeted because of previous evidence of iron buildup in
Alzheimer’s patients, which both of these genes play a role in metabolizing44–46. In 2009, Kauwe
et al. replicated the findings from Robson et al. in a separate cohort22. There is strong evidence of
4

a biological cascading effect for this statistical interaction, as suggested by Kauwe et al.22. HFE
binds with transferrin receptor 1 (TfR1), but the C282Y allele has a lesser affinity, allowing
TfR1 to bind TF more easily22,47. It was hypothesized that more aggressive binding of TF may
cause over absorption of dietary iron, leading to iron deposits in various tissues22,48. Additionally,
Giunta et al. suggested wild-type TF plays an important role in iron transport and limits amyloid
aggregation22,49. All of this information supports hypotheses by Robson et al.21 and Lehmann et
al.50 that this interaction increases LOAD risk through increased redox-active iron and oxidative
Stress.
Likewise, in 2004 Infante et al. identified statistical epistasis between interleukin-6 (IL-6)
and interleukin-10 (IL-10) associated with decreased risk for Alzheimer’s disease based on
previous evidence that patients with Alzheimer’s disease produce more pro-inflammatory
interleukin-6 and less anti-inflammatory interleukin-1051. In 2009 Combarros et al. replicated the
statistical interaction in a separate cohort18. This interaction may play a critical role in LOAD
because Remarque et al. demonstrated that Alzheimer’s disease patients have a pro-inflammatory
phenotype and that Alzheimer’s disease patients produce more IL-6 (pro-inflammatory) and less
IL-10 (anti-inflammatory) when compared to controls52. It is difficult to determine, however,
whether this inflammation is contributing to Alzheimer’s disease, or is simply another side effect
of the underlying cause.
In 2009, Combarros et al. performed a comprehensive analysis of over 100 reports of
statistical epistasis, using and introducing their own synergy factor statistic. This study highlights
the innate challenges in discovering statistical epistasis. The authors were only able to support 27
of the originally reported gene-gene interactions using their synergy factor analysis. The
challenge with epistatic replication is that there are many factors that influence whether the
5

interaction can be detected in a given data set. Sample size, heterogeneity, and environmental
factors are likely the most influential for detecting a real interaction.
In 2014, Gusareva et al. published the first replicable interaction associated with LOAD
using an exhaustive, genome-wide screening approach53. They identified an interaction between
KHDRBS2 (rs6455128) and CRYL1 (rs7989332) using a cohort from France including 2,259
cases and 6,017 controls. The interaction was then replicated in a cohort from Germany
including 555 cases and 824 controls. The interaction was further supported by a meta-analysis
using five more independent LOAD cohorts. Transcriptome analysis showed decreased
expression for both genes in the temporal cortex and cerebellum brain regions. Gusareva et al.
hypothesized a biological link between KHDRBS2 and CRYL1 through a potential association
with heat-shock proteins and LOAD. KHDRBS2 is believed to affect transcription of heat-shock
proteins because of studies in it’s homologue Slm1 in Saccharomyces cerevisiae53,54. Slm1 was
shown to interact with and activate TORC255, a kinase complex part of the TOR pathway, which
Pierce et al. demonstrated affects amyloid β and cognitive function in Alzheimer’s disease mouse
models56. Pierce et al. hypothesized the reason inhibiting the TOR pathway affects amyloid β and
cognition because of upregulated heat-shock proteins. This study in particular, represents the
next step in discovering and describing functional repercussions of epistasis.
Epistasis Among Top LOAD Genes
Most epistasis studies in LOAD involve candidate genes, but to date, no study has
addressed possible interactions between the top LOAD genes as found on AlzGene.org (accessed
December 2014). These genes include the following: APOE, BIN1, ABCA7, CR1, MS4A4E,
CD2AP, PICALM, MS4A6A, CD33, and CLU. BIN1 (rs744373), ABCA7 (rs3764650), CR1
(rs3818361), MS4A4E (rs670139), and CD2AP (rs9349407) are associated with increased risk
6

for LOAD while PICALM (rs3851179), MS4A6A (rs610932), CD33 (rs3865444), and CLU
(rs11136000) are associated with decreased risk (6-10). Only one study to date, by Verhaaren et
al., has examined the contribution of these nine risk alleles to LOAD status prediction (11).
Verhaaren et al. calculated an additive genetic risk score and compared LOAD status prediction
performance of age, gender, and APOE ε4 genotype using logistic regression with and without
the additive genetic risk score. The genetic risk score did not improve prediction performance
significantly, suggesting that the nine alleles may not be diagnostically useful when constrained
to an additive relationship. The assumption of additive relationships between risk loci is common
but is likely to be an oversimplification of the underlying biology for LOAD and other complex
diseases (12-14). In fact, there may be underlying gene-gene interactions not examined in the
Verhaaren et al. study or others that improve LOAD status prediction performance.
In this dissertation we evaluate the possible interactions between these variants and their
effects on Alzheimer’s disease in several large, independent datasets and develop software to
facilitate follow-up of genetic findings using whole genome sequence data. The first chapter
describes my efforts to explore the effects of interactions on the diagnostic capabilities of known
AD risk markers. Briefly, we genotyped each locus in 2,419 subjects from the Cache County
Study on Memory Health and Aging and verified results by Verhaaren et al., but also explored
statistical epistasis among the loci to determine if any interactions are informative to the model
in the presence of the main (individual) allele affects. Two interactions were significant in the
model: an interaction between CD33 and MS4A4E (p < 0.003; SF 5.31, 95% CI 1.79 - 15.77),
and between CLU and MS4A4E (p < 0.016; SF 3.81, 95% CI 1.28 - 11.32).
In subsequent chapters we describe novel software and our efforts to replicate these genegene interactions by performing an independent meta-analysis of datasets from the Alzheimer’s
7

Disease Genetics Consortium (ADGC), followed by a combined meta-analysis including the
original Cache County data. This work includes evaluation of dosage effects in both interactions
and an APOE ε4 effect as well as a permutation experiment to test robustness of results that had a
significant p-value in the independent analysis. Finally, we explored possible causal variants that
underlie this interaction using whole-genome sequence data from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI).
Future Directions
Many researchers are focusing their efforts on epistasis and the community is beginning
to discover epistatic interactions that play a role in LOAD. The work outlined in this dissertation,
which leveraged the use of markers known to show association with AD risk, supports an
interaction between CLU and MS4A4E and is an important piece in understanding LOAD
etiology. Each of the top candidate genes has a consistent and strong signal across numerous data
sets, making it a reasonable hypothesis that there are interactions between them. It is not
reasonable, however, to assume that the most critical interactions are only between loci with
main effects. As such, researchers must approach epistasis in LOAD with even larger data sets
using exhaustive, genome-wide approaches as demonstrated by the exciting study by Gusareva et
al.
The International Genomics of Alzheimer’s Project (IGAP) has a data set of over 74,000
cases and controls57—a massive data set by today’s standards. Given the success by Gusareve et
al., a similar agnostic (hypothesis-free) approach in such a large data set will likely result in
more, stable interactions associated with LOAD case-control status, thus leading to potentially
useful approaches for both diagnostics and therapeutics. IGAP also discovered several more
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alleles with main effects in a recent study57. Rerunning our analysis across the top loci including
IGAP’s newly discovered loci may uncover new interactions.
Ultimately, however, we must bridge the gap between statistical and biological epistasis.
Biological experiments demonstrating tangible effects on known or novel LOAD pathology will
be essential to understanding the underlying etiology. These gene-gene interactions may involve
physical interactions between proteins, or they may be indirect where they affect a downstream
product.

9
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Abstract
Background. Reported odds ratios and population attributable fractions (PAF) for lateonset Alzheimer’s disease (LOAD) risk loci (BIN1, ABCA7, CR1, MS4A4E, CD2AP, PICALM,
MS4A6A, CD33, and CLU) come from clinically ascertained samples. Little is known about the
combined PAF for these LOAD risk alleles and the utility of these combined markers for casecontrol prediction. Here we evaluate these loci in a large population-based sample to estimate
PAF and explore the effects of additive and non-additive interactions on LOAD status prediction
performance.
Methods. 2,419 samples from the Cache County Memory Study were genotyped for
APOE and nine LOAD risk loci from AlzGene.org. We used logistic regression and ROC
analysis to assess the LOAD status prediction performance of these loci using additive and nonadditive models and compared ORs and PAFs between AlzGene.org and Cache County.
Results. Odds ratios were comparable between Cache County and AlzGene.org when
identical SNPs were genotyped. PAFs from AlzGene.org ranged from 2.25-37%; those from
Cache County ranged from 0.05-20%. Including non-APOE alleles significantly improved
LOAD status prediction performance (AUC = 0.80) over APOE alone (AUC = 0.78) when
allowing allelic interactions (p = 0.03). We also identified potential allelic interactions (p-values
uncorrected): CD33-MS4A4E (Synergy Factor = 5.31; p = 0.003) and CLU-MS4A4E (SF = 3.81;
p = 0.016).
Conclusions. While non-additive interactions between loci significantly improve
diagnostic ability, the improvement does not reach the desired sensitivity or specificity for
clinical use. Nevertheless, these results suggest that understanding gene-gene interactions may be
important in resolving the etiology of Alzheimer’s disease.
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Introduction
Researchers have implicated several genes associated with late-onset Alzheimer’s disease
(LOAD) including APOE. APOE ε4 increases LOAD risk and APOE ε2 reduces risk (1-4).
According to AlzGene.org (5), nine additional genes significantly affect LOAD risk; BIN1
(rs744373), ABCA7 (rs3764650), CR1 (rs3818361), MS4A4E (rs670139), and CD2AP
(rs9349407) are associated with increased risk for LOAD while PICALM (rs3851179), MS4A6A
(rs610932), CD33 (rs3865444), and CLU (rs11136000) are associated with decreased risk (6-10).
Only one study to date has examined the contribution of these nine risk alleles to LOAD status
prediction (11). Verhaaren et al. calculated an additive genetic risk score and compared LOAD
status prediction performance of age, gender, and APOE ε4 genotype using logistic regression
with and without the additive genetic risk score. The genetic risk score did not improve
prediction performance significantly, suggesting that the nine alleles may not be diagnostically
useful when constrained to an additive relationship. The assumption of additive relationships
between risk loci is common but is likely to be an oversimplification of the underlying biology
for LOAD and other complex diseases (12-14). In fact, there may be underlying gene-gene
interactions not examined in the Verhaaren et al. study or others that improve LOAD status
prediction performance.
Some of the population attributable fractions for these nine loci have been reported
individually and in different combinations (6, 8, 9); however, no study to date has reported the
combined population attributable fraction for all nine risk alleles. Furthermore, previously
reported odds ratios and population attributable fractions are from clinically ascertained samples
rather than a population-based sample (6-10). The latter may provide a more reliable measure of
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population risk because clinically ascertained samples select for disease, enriching risk alleles in
the sample.
In this study we estimated the allelic odds ratios and population attributable fractions for
APOE ε2, APOE ε4, and the nine non-APOE LOAD risk alleles in a large population-based
sample. We also extended the genetic risk score used by Verhaaren et al. by testing whether the
nine non-APOE alleles contribute significantly to LOAD status prediction when interactions
between loci are not constrained to additive relationships.
Methods and Materials
Sample collection. The Cache County Study on Memory Health and Aging was initiated
in 1994 (15). This cohort of 5,092 individuals represented approximately 90% of the Cache
County population aged 65 and older. Specific details about data collection, obtaining consent,
and phenotyping individuals in the Cache County population have been reported previously (15).
Briefly, case-control status was determined in four triennial waves of data collection in a multistage dementia screening and assessment protocol. The first stage of screening consisted of
administration of the Modified Mini-Mental State Exam-Revised (3MS-R) (16). Screen positive
individuals and a randomly selected 19% designated subsample were invited to complete
subsequent stages of evaluation consisting of an informant interview and the next stage, a
clinical assessment including neuropsychological testing. The clinical assessment results were
reviewed by a geropsychiatrist and neuropsychologist and preliminary diagnoses of dementia or
other cognitive disorders were assigned. Those carrying a diagnosis of dementia or its prodrome
were invited to complete standard laboratory tests for dementia, an MRI scan, and a
geropsychiatrist examination. Final case-control status was determined by an expert panel of
clinicians including study geropsychiatrists, neuropsychologists, a neurologist and cognitive
20

neuroscientist. Diagnoses of AD followed NINCDS-ADRDA criteria (17), and cases included
Possible or Probable AD. Controls were identified as those who were diagnosed with no
dementia (per clinical assessment) or whose cognitive test result was negative at each preceding
screening stage. Persons with incomplete screening results (i.e., those who were screen positive
at one stage, but did not complete the subsequent stage), or missing genotype data were excluded
from the analyses, leaving 2093 participants without dementia (controls) and 326 persons with
LOAD (cases). All study procedures were approved by the Institutional Review Boards of Utah
State, Duke and the Johns Hopkins University.
DNA from the 2,419 Cache County study participants was genotyped for the nine nonAPOE LOAD risk alleles in the AlzGene.org “ALZGENE TOP RESULTS” list (18) using
TaqMan Assays (Table 2.1). Genotyping failed for rs3764650 (ABCA7) and rs3818361 (CR1) so
we selected rs3752246 and rs6656401 to represent the effects reported by ABCA7 and CR1 for
AD risk, respectively. The CR1 SNPs are in high linkage disequilibrium (D’ = 0.995, R2 = 0.84)
while both ABCA7 SNPs are within 10 kilobases of each other and rs3752246 was reported as
significant by Naj et al. (9) APOE ε2 and APOE ε4 were previously genotyped as part of the
Cache County study (15).
Statistical analyses. All statistical analyses were performed in R (19). We used logistic
regression and receiver operating characteristic (ROC) curve analysis to assess case-control
predictive performance of the nine non-APOE alleles. Specifically, we tested whether the nonAPOE alleles significantly improved LOAD status prediction performance over models
excluding the non-APOE alleles. Two types of models were generated: additive risk profiles and
genotype models to test potential additive and non-additive relationships, respectively. To assess
efficacy of each model, we measured LOAD status prediction performance using the area under
21

Table 2.1. Summary Statistics for Significant Markers
MAF
SNP
rs3752246*
rs7412
rs429358
rs744373
rs9349407
rs3865444
rs11136000
rs6656401
rs670139
rs610932
rs3851179

Nearest Gene
ABCA7
APOE2
APOE4
BIN1
CD2AP
CD33
CLU
CR1
MS4A4E
MS4A6A
PICALM

Odds Ratio

AlzGene

Cache Co.

0.10
0.06
0.22
0.29
0.29
0.31
0.38
0.19
0.41
0.42
0.35

0.18
0.09
0.17
0.30
0.28
0.34
0.39
0.19
0.41
0.43
0.38

AlzGene (95% CI)

Cache Co. (95% CI)

1.23 (1.18 - 1.28)
0.94 (0.76 - 1.17)
0.62 (0.46 - 0.85)
0.89 (0.63 - 1.22)
3.68 (3.30 - 4.11)
2.51 (2.07 - 3.04)
1.17 (1.13 - 1.20)
1.02 (0.85 - 1.22)
1.12 (1.08 - 1.16)
1.03 (0.85 -1.23)
0.89 (0.86 - 0.92)
1.00 (0.84 - 1.19)
0.88 (0.86 - 0.91)
0.88 (0.74 - 1.04)
1.19 (1.09 - 1.30)
0.92 (0.74 -1.13)
1.08 (1.05 - 1.11)
1.0 (0.84 - 1.18)
0.90 (0.88 - 0.93)
0.89 (0.76 -1.06)
0.88 (0.86 - 0.91)
0.85 (0.72 - 1.01)
Combined PAF (All Alleles)
Combined PAF (Excluding APOE)

PAF
AlzGene Cache Co.
2.25
36
37
4.61
3.29
7.63
7.85
3.49
3.14
5.81
8.19
75
38

4.65
10
20
0.54
0.70
0.05
7.98
6.84
0.05
6.33
9.69
51
32

Note. Minor allele frequencies, odds ratios, and population attributable risks were calculated for all SNPs using both data from AlzGene.org and the Cache
County population-based study. Population attributable fractions are reported as percentages. For better interpretation and comparison to previous studies, the
risk allele for each locus (whether the major or the minor allele) was used to calculate population attributable fractions but the minor allele was used for odds
ratios. Minor allele frequencies are comparable between AlzGene.org and the Cache County data. Odds ratios are generally similar except ABCA7 and CR1 differ
in direction. Individual population attributable fractions in Cache County varied in magnitude when compared to those calculated for AlzGene.org. Combined
population attributable fractions were also lower in Cache County. As expected APOE ε4 and APOE ε2 have strong population effects whereas the remaining
alleles have minimal individual effect. Based on AlzGene.org data, combined population attributable fractions suggest the combined effect of the nine non-APOE
alleles is approximately equal to APOE ε2 or APOE ε4 alone; however, the nine non-APOE alleles appear to have a larger effect than either APOE allele in the
Cache County data.
*The SNP for ABCA7 (rs3752246) was not reported on AlzGene.org, but was reported in Naj et al. as significant and was used in place of rs3764350

22

the curve (AUC) of the ROC curves. All models were adjusted for age and gender. A separate
model using only age and gender was also generated to establish reference values.
We calculated three additive risk scores for participants in the Cache County Study to
measure LOAD status prediction performance for the nine non-APOE LOAD risk alleles.
Specifically, the following risk profiles were calculated: (1) APOE alone; (2) the nine LOAD
risk alleles with APOE; and (3) the nine LOAD risk alleles without APOE. The risk allele
(whether the major or the minor allele) and associated beta coefficient were used for each locus.
We calculated additive risk scores as the sum of the risk across all alleles (equation 2.1), where β
equals a previously calculated risk allele beta coefficient from odds ratios (β = ln(odds ratio))
reported by AlzGene.org (accessed February 2012), and N equals the subject’s number of risk
alleles. APOE ε2 and APOE ε4 were coded jointly into a single class variable as 22, 23, 24, 33,
34, and 44.
(2.1)
We also tested genotype models using genotype data in place of the risk profile score. We
generated the following genotype models: (1) APOE alone; (2) the nine LOAD risk alleles with
APOE; and (3) an optimized model. Using genotypes does not constrain the model to an additive
relationship, allowing for other genetic models within each locus. The optimized model was
generated using a stepwise regression method to test if interactions between loci contribute to
LOAD status prediction and was selected using Akaike’s information criterion (AIC). To test for
and avoid overfitting, we included three random variables while generating the optimized model.
These variables were generated randomly with respect to all genotype and phenotype data in our
study and were included to provide evidence that the selected variables provide meaningful
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information (20). While the absence of all random variables in the model does not guarantee the
model was not overfit, it does suggest the included variables provide useful diagnostic
information.
Synergy factors—a statistic that measures the strength of allelic interactions in casecontrols studies (13, 21)—were calculated for any statistically significant allelic interactions
using logistic regression. All synergy factors were adjusted for age, gender, and APOE ε4 by
including only the main effects of the interacting alleles, the interaction term between the alleles,
age, gender, and the number APOE ε4 alleles (Status = allele1*allele2 + age + gender +
APOE4num). Synergy factor confidence intervals were calculated using the interaction term
coefficient ±1.96 * standard error of the parameter estimate of the interaction term.
Odds ratios and population attributable fractions were also calculated. Odds ratios here
estimate the relative risk of Alzheimer’s disease given allelic exposure while population
attributable fractions estimate the proportional decrease in LOAD cases that would occur if the
risk factor were removed from the population. Odds ratios were calculated only for the Cache
County subjects but population attributable fractions were calculated for both Cache County
subjects and the pooled AlzGene samples using published odds ratios and minor allele
frequencies from AlzGene.org. We calculated population attributable fractions using equation
2.2 (9, 22), where p equals the allele frequency and OR is the odds ratio. A combined population
attributable fraction was calculated for all risk factors and just the nine non-APOE risk factors
using equation 2.3 (9, 22, 23) to estimate the proportional decrease in LOAD cases if all included
risk factors were removed from the population. In this equation PAFj represents previously
calculated PAFs from equation 2.2 and n is the number of loci included in the combined PAF.
For better interpretation and comparison to previous studies, the risk allele for each locus
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(whether the major or the minor allele) was used to calculate population attributable fractions but
the minor allele was used for odds ratios.
(2.2)

(2.3)
Results
Sample demographics. The sample consisted of 1406 females and 1013 males. The
mean age and standard deviation were 75.13 and 7.29 years, respectively. Mean age was
significantly different between cases and controls (p = 2.2e-16), as were the proportion of males
in each group (p = 0.04; Supplemental Table 2.1). Similarly, mean age was significantly different
between participants included in the study and those excluded for reasons previously mentioned
(p = 2.2e-16; Supplemental Table 2.2). The proportion of males, however, was not significantly
different between included and excluded participants (p = 0.29).
Odds ratios. Odds ratios calculated for the Cache County data were generally
comparable in direction and magnitude to odds ratios from AlzGene.org when identical SNPs
were genotyped. ABCA7 and CR1 varied, but a different SNP was genotyped for ABCA7 and the
95% confidence intervals for CR1 overlap between AlzGene.org and Cache County results
(Table 2.1). Odds ratios from meta-analyses on AlzGene.org for ABCA7 and CR1 are 1.23 (95%
CI 1.18 – 1.28) and 1.19 (95% CI 1.09 – 1.30), respectively, while from the Cache County data
were 0.94 (95% CI 0.76 – 1.17) and 0.92 (95% CI 0.74 – 1.13), respectively. No alleles deviated
significantly from Hardy Weinberg equilibrium.
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Population attributable fraction. Population attributable fractions as calculated from
AlzGene.org data ranged from 2.25% to 37% while those from Cache County ranged from
0.05% to 20% (Table 2.1). The highest risks were attributed to APOE ε4 (AlzGene = 37%;
Cache = 20%) and lack of the APOE ε2 (AlzGene = 36%; Cache = 10%) whereas the next
highest risk was attributed to PICALM (AlzGene = 8.19%; Cache = 9.69%). The smallest risk for
AlzGene.org was from ABCA7 (2.2%) while the smallest for the Cache County data were CD33
and MS4A4E (0.05%). Combined population attributable fractions for all LOAD risk alleles
(including APOE) were 75% and 51% for AlzGene.org and Cache County, respectively. Using
only the nine non-APOE alleles were 38% and 32% for AlzGene.org and Cache County,
respectively.
LOAD status prediction performance. The non-APOE alleles combined with APOE
(AUC = 0.782) did not improve LOAD status prediction performance over APOE alone (AUC =
0.783) when constrained to an additive model (Supplemental Figure 2.1), as previously reported
(11); nor did the non-APOE alleles without APOE (AUC = 0.728) significantly improve LOAD
status prediction performance over age and gender alone (AUC = 0.727; p = 0.2372). The model
using all genotype data (full genotype model) when not constrained to an additive relationship
(AUC = 0.796), however, did improve LOAD status prediction performance significantly over
APOE alone (AUC = 0.783; p = 0.03; Figure 2.1). Moreover, the optimized model allowing for
interactions between loci (AUC = 0.82) improves significantly over the full genotype model (p =
8.39e-07). All three genotype models improve prediction performance significantly over age and
gender alone. None of the random variables previously mentioned were selected for the
optimized model. Selected variables and interactions for the optimized model are as follows:
rs3752246, rs6656401, rs11136000, rs610932, rs3865444, rs670139, Age, APOE.factor,
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rs3865444:rs670139, rs11136000:rs670139, rs3752246:APOE.factor, rs3752246:rs610932, and
rs670139:Age.
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Figure 2.1. Non-APOE LOAD risk loci contributions to LOAD status prediction
performance. Three logistic regression models based on age, gender, and genetic information
for APOE and the non-APOE LOAD risk loci illustrate the contribution of the non-APOE LOAD
risk loci in LOAD status prediction performance. The models are as follows: APOE alone (Only
APOE), all loci (Full genotype), and the optimized model (Optimal genotype). A fourth model
using only age and gender (Age/Gender) was also generated as a baseline. The optimized model
was optimized using Akaike’s Information Criterion (AIC). Comparing the full genotype model
to APOE alone demonstrates that the LOAD risk loci contribute significantly to LOAD status
prediction performance (p = 0.03) while the optimized model improves significantly over the full
genotype model (p = 8.39e-07). Area under the curve (AUC) is listed in parentheses within the
legend.
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Locus interactions. Investigating the optimized genotype model revealed two
statistically significant alleles and two significant allelic interactions, though the p-values were
not corrected for multiple testing. Genotypes A/G (p = 0.02) and G/G (p = 0.03) in rs6656401
(CR1) were significant individually. The significant interactions were between the rs3865444
C/C (CLU) genotype and the rs670139 G/G (MS4A4E) genotype (p = 0.016; SF 3.81, 95% CI
1.28 - 11.32) and the rs11136000 C/C (CD33) genotype and the rs670139 G/G (MS4A4E)
genotype (p = 0.003; SF 5.31, 95% CI 1.79 - 15.77).
Discussion
Recent research has identified several alleles that may prove useful in resolving
Alzheimer’s disease etiology (6-10), but until now there had not been an assessment of their
population attributable fraction in a large, population-based sample. Similarly, deeper
interrogation of the diagnostic utility of the Alzheimer’s disease candidate genes is needed.
Verhaaren et al. explored the diagnostic utility based on an additive relationship, which we
replicated in this work, but they did not test locus interactions—a major aim of this research.
During this process we also estimated allelic odds ratios and population attributable fractions.
The data reported in this study are generalizable to other U.S. populations of northern
European descent. The Cache County population has been included in the Centre d’Etude du
Polymorphisme Humain (CEPH) families that are used to represent the European sample in the
HapMap project (24, 25). Utah’s early pioneers were mostly unrelated and originated from
various European locations (26-28), which is necessary for generalizability. The AlgGene.org
data—a meta-analysis—varies between loci but is largely Caucasian-based as well. Many of the
loci include populations of African, Asian, and Hispanic decent but the sample sizes for these
populations are much smaller than the Caucasian populations.
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Odds ratios. We compared Cache County odds ratios to those reported in the metaanalyses on AlzGene.org and found them comparable. Minor differences were observed in
ABCA7 and CR1 where we genotyped SNPs that are not listed on AlzGene.org. Specifically,
minor alleles for both ABCA7 and CR1 were considered risk alleles (odds ratio > 1) according to
data on AlzGene.org while odds ratios in the Cache County data suggest decreased risk, although
the confidence intervals from both studies are broad and overlap each other so they may not be
significantly different. Possible causes include: (1) differences in sample ascertainment between
clinical and population studies (e.g. the cases in clinically ascertained samples are generally
younger than those in the Cache County Sample; see AlzGene.org, Supplemental Table 2.1); and
(2) allelic odds ratios are not adjusted for age, gender, and other loci—nor are they adjusted for
undiscovered or uncharacterized allelic interactions (13, 29-31).
Clinical and population studies differ in sample ascertainment. Clinically ascertained
cases and controls are selected to minimize confounding variables and maximize contrast
between the true underlying causes by minimizing known differences between the two groups
except for the phenotype of interest. Population-based studies, however, are designed to
represent true population characteristics such as allele frequencies, odds ratios, and population
attributable fractions, as reported here. Because of the natural differences between these two
study types, it is important to use them to their greatest advantage.
The complex nature of Alzheimer’s disease inheritance, however, suggests that variations
between studies may be exist because allelic odds ratios are not adjusted for age, gender, and
other loci—nor are they adjusted for undiscovered and uncharacterized allelic interactions. Each
of these factors plays a significant role in Alzheimer’s disease etiology and not adjusting for
them introduces error into odds ratio estimates. Allelic interactions also likely contribute to the
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“missing heritability” in Alzheimer’s disease. No single genetic locus characterizes Alzheimer’s
disease etiology. APOE alone is highly predictive, but the genetic loci included here also appear
to influence Alzheimer’s disease susceptibility, as reported in this study and others (6-10).
Furthermore the effects of APOE vary between ethnic groups (32-36). Failure to replicate
established genome-wide association study findings in some populations (13, 37) further
suggests the possible influence of environmental factors, gene-environment, and gene-gene
interactions.
Population attributable fractions. Cache County population attributable fractions
varied in magnitude when compared to those calculated from AlzGene.org data. Combined
population attributable fractions were lower in Cache County. As expected APOE ε4 and APOE
ε2 have strong population effects whereas the remaining alleles have minimal individual effects.
Based on AlzGene.org data, combined population attributable fractions suggest the combined
effect of the nine non-APOE alleles is approximately equal to APOE ε2 or APOE ε4 alone;
however, the combined non-APOE alleles appear to have a larger effect than either APOE allele
in the Cache County data. The Cache County values are of value because they are populationbased and better represent risks within populations—the purpose of the PAF statistic. Despite
being more conservative than other estimates (combined), however, the population attributable
fractions reported in this study may still be inflated because they are based on the unadjusted
allelic odds ratios and because the exposure frequency for the genotyped SNPs may vary from
the functional variants they represent. Future estimates are also likely to change as allelic
interactions are discovered and incorporated into the calculations.
Diagnostic utility. Verhaaren et al. demonstrated that the nine non-APOE genes do not
improve LOAD status prediction performance when constrained to an additive relationship,
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which we confirmed in this study. When unconstrained, however, the top nine alleles improved
LOAD status prediction performance significantly, demonstrating these alleles may provide
more information as we better understand their epistatic relationships. The optimized model
further improved LOAD status prediction performance and revealed CLU-MS4A4E and CD33MS4A4E interactions that may prove valuable in Alzheimer’s disease research. Synergy factors
for both interactions suggest that being homozygous for both alleles in either interaction
increases risk. Yet, although these data suggest the additional LOAD risk alleles significantly
improve LOAD status prediction performance, the improvement is marginal and does not reach
the desired sensitivity or specificity for clinical use.
The optimized model clearly improves LOAD status prediction performance over the full
genotype model and over APOE alone, suggesting allelic interactions may be useful for
diagnostic purposes; however, the p-values were not corrected for multiple testing. As such,
these interactions need to be tested in an independent data set. It is also possible the optimized
model is overfit; however, the random variables included in the model selection process were not
selected for the final model, lending evidence that the final variables included provide nonrandom information. The revealed interactions also have strong synergy factors suggesting they
may be important. Furthermore, the genotype model with all alleles improves LOAD status
prediction performance over APOE alone, lending support for underlying relationships amongst
the factors included in the model.
Implications and future directions. The results presented here offer evidence that genegene interactions play a role in Alzheimer’s disease susceptibility; however, the reported
interactions, do not appear to improve LOAD status prediction performance by an amount that is
relevant in a clinical diagnostic setting. These results do suggest that to fully understand the
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genetic basis of Alzheimer’s disease risk we must improve our efforts to characterize gene-gene
and gene-environment interactions.
Additionally, environmental factors have not received as much attention as genetic
factors in Alzheimer’s disease research and should be thoroughly investigated (12). Although the
CLU-MS4A4E and CD33-MS4A4E interactions appear to have strong effects in the Cache
County study, there may be unmeasured environmental factors that increase the effect of these
interactions in the Cache County population. Other research has shown that only 30% of
Alzheimer’s disease is explained by known genes, demonstrating that environmental effects and
gene by environment interactions will be essential in future studies (38).
The CLU-MS4A4E and CD33-MS4A4E interactions have not been previously reported
leaving the biological foundation in question. Using IPA (Ingenuity® Systems,
www.ingenuity.com), we explored possible interactions between each pair and found that, while
no information is available for MS4A4E specifically, both CLU and CD33 interact indirectly with
MS4A2 (Supplemental Figures 2.2 and 2.3). According to IPA, both thioacetamide and TGFB1
act indirectly on both CLU and MS4A2 (Supplemental Figure 2.2). CLU also binds to BCL2L1,
which is acted upon by MS4A2. Likewise, CD33 acts on PTPN6, which binds to MS4A2 and
CD33 binds to CBL, which then acts on MS4A2 (Supplemental Figure 2.3). Both MS4A4E and
MS4A2 are members of the membrane-spanning 4-domain gene family. A complete IPA legend
is available in Ingenuity’s website
(http://ingenuity.force.com/ipa/articles/Feature_Description/Legend).
Overall, the results presented in this paper suggest that gene-gene interactions (epistasis)
may play an important role in Alzheimer’s disease etiology. While discovering and
characterizing epistatic interactions is a non-trivial task, researchers and consortiums must heed
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the plentiful evidence that Alzheimer’s disease is driven by complex gene-gene and geneenvironment interactions.
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Supplemental Table 2.1. Demographic Comparison between Cases and Controls Included in the
Study Analysis
Age

Cases
Controls
n
p-value

Gender

Mean

Standard
Deviation

80.17
74.34

7.24
6.68

= 2.2e-16

Male

Female

n

119
894
1013

207
1199
1406

326
2093
2419

Proportion
of
Females
0.63
0.57
= 0.04

Note. The mean age between cases and controls included in the study were significantly different as are the
differences in the proportion of females.
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Supplemental Table 2.2. Demographic Comparison between Participants Included and
Excluded in the Analysis
Age

Included
Excluded
n
p-value

Gender

Mean

Standard
Deviation

75.13
77.33

6.92
7.48

= 2.2e-16

Male

Female

n

1013
1074
2087

1406
1399
2805

2419
2473
4892

Proportion
of Females
0.58
0.57
= 0.29

Note. The mean age between participants included and those excluded were significantly different, but the
proportion of females was not. One possible cause of this difference is that samples excluded for missing genotype
data were significantly older than those that were included. This is likely because the majority of DNA samples
come from the original buccal swabs. These samples have lower call rates than the blood DNA that was collected at
later waves of assessment. As a result, the individuals who were oldest at the start of the study have higher genotype
missing rates. This results in the slightly higher age of excluded samples over included samples. However, unless
there is a loss of individuals who go on to develop AD vs. those who remain non-demented this unlikely to bias our
results. There is no evidence for such a bias.
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Supplemental Figure 2.1. Non-APOE LOAD risk loci contributions to LOAD status
prediction performance under additive constraints. The non-APOE alleles combined with
APOE did not improve LOAD status prediction performance over APOE alone when constrained
to an additive model; nor did the non-APOE alleles without APOE significantly improve LOAD
status prediction performance over age and gender alone (p = 0.2372). Area under the curve
(AUC) is listed in parentheses within the legend.
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Supplemental Figure 2.2. CLU-MS4A4E pathway analysis. Pathway analysis using
Ingenuity’s IPA demonstrates evidence that both CLU and CD33 interact indirectly with MS4A2,
a member of the membrane-spanning 4-domain gene family, as is MS4A4E. Both thioacetamide
and TGFB1 act indirectly on both CLU and MS4A2 (Supplemental Figure 2). CLU also binds to
BCL2L1, which is acted upon by MS4A2. Likewise, CD33 acts on PTPN6, which binds to
MS4A2 and CD33 binds to CBL, which then acts on MS4A2 (Supplemental Figure 3). No
information regarding MS4A4E specifically was available in IPA. An exhaustive legend
describing the molecules and interactions are available on Ingenuity’s website
(http://ingenuity.force.com/ipa/articles/Feature_Description/Legend).
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Supplemental Figure 2.3. CD33-MS4A4E pathway analysis. Pathway analysis using
Ingenuity’s IPA demonstrates evidence that both CLU and CD33 interact indirectly with MS4A2,
a member of the membrane-spanning 4-domain gene family, as is MS4A4E. Both thioacetamide
and TGFB1 act indirectly on both CLU and MS4A2 (Supplemental Figure 2). CLU also binds to
BCL2L1, which is acted upon by MS4A2. Likewise, CD33 acts on PTPN6, which binds to
MS4A2 and CD33 binds to CBL, which then acts on MS4A2 (Supplemental Figure 3). No
information regarding MS4A4E specifically was available in IPA. An exhaustive legend
describing the molecules and interactions are available on Ingenuity’s website
(http://ingenuity.force.com/ipa/articles/Feature_Description/Legend).
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Abstract
Background. Since the advent of next-generation sequencing many previously untestable
hypotheses have been realized. Next-generation sequencing has been used for a wide range of
studies in diverse fields such as population and medical genetics, phylogenetics, microbiology,
and others. However, this novel technology has created unanticipated challenges such as the
large numbers of genetic variants. Each Caucasian genome has more than 4 million single
nucleotide variants, insertions and deletions, copy number variants, and structural variants.
Several formats have been suggested for storing these variants; however, the variant call format
(VCF) has become the community standard.
Results. We developed new software called the Variant Tool Chest (VTC) to provide
much needed tools to work with VCF files. VTC provides a variety of tools for manipulating,
comparing, and analyzing VCF files beyond the functionality of existing tools. In addition, VTC
was written to be easily extended with new tools.
Conclusions. Variant Tool Chest brings new and important functionality that
complements and integrates well with existing software. VTC is available at
https://github.com/mebbert/VariantToolChest
Background
The variant call format (VCF) has become the standard format for storing variants
identified in next-generation sequencing (NGS) and other studies. VCF files are flexible with
eight fixed fields including chromosome (CHROM), position (POS), known variant IDs such as
dbSNP identifications (ID), reference allele (REF), alternate allele(s) (ALT), variant quality
score (QUAL), filter information summarizing why a variant was or was not considered valid by
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the variant calling software (FILTER), and an information field (INFO). Additional fields
containing genotypes for one or more samples may also be present. Each row of the file contains
information about observed variants at the given position and chromosome, may have
information about how the variant(s) was/were identified (allele frequency, depth, strand bias,
genotype likelihoods, etc.), and biological annotations (gene, variant frequency, 1000 Genomes
membership, mRNA and protein positions, etc.). The last columns of a VCF file contain
genotype information specifying whether the individual is heterozygous, homozygous reference
or variant, or whether it is unknown (missing). Finally, VCF files can contain information for a
single or multiple samples. Alternatively, summary VCF files containing minimal information
(chromosome, position, reference allele, variant allele, and genotypes) can be used. VCF files are
used to store all variant types including single nucleotide variants, insertions and deletions, copy
number variants, and structural variants. The VCF has become an important format in modern
biology and is the only widely used format for variant storage.
Several programs exist for manipulating and comparing VCF files: VCF tools [1],
BedTools [2], BcfTools, and the Genome Analysis Toolkit (GATK) [3, 4]. Each of these
softwares is flexible and powerful, but missing certain essential features. In this manuscript we
describe a novel program, the Variant Tool Chest (VTC). The Variant Tool Chest complements
existing softwares by extending their capabilities without replicating existing solutions for
working with VCF files. We also provide suggestions for building upon the VTC rather than
building new tools from scratch. VTC can be downloaded at
https://github.com/mebbert/VariantToolChest.
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Results and Discussion
Novel features. Multi-sample VCF support. As next-generation sequencing continues to
gain momentum, researchers need the ability to compile many samples into a single VCF or
analyze variants from multiple VCF files. VTC was built to work with a combination of multiand single-sample VCF files. Existing softwares are only capable of handling either a single
VCF file, or one multi-sample VCF file. VTC can handle a mix of single and multi-sample VCF
files, with the user defining which sample(s) to use from each of the VCF files.
Genotype set operations. VTC contains a powerful set operation tool named
“SetOperator” designed to perform simple or complex set operations using VCF files, including
intersects, complements, and unions. While various tools exist to perform set operations on VCF
files, VTC improves existing solutions in two ways. First, existing software performs set
operations based only chromosome and base pair position. This means that if one individual is
heterozygous and another homozygous, the resulting operations would assume that these two
individuals have the same genotype. Second, existing tools work on only a collection of single
sample VCF files. In contrast, VTC can perform set operations on a single multi-sample VCF
file, or a combination of multi- and single sample VCF files. Furthermore, the user can choose to
only perform the operations based on certain individuals from each multi-sample VCF file.
These abilities save researchers time by not forcing the user to extract all samples of interest into
a collection of single sample VCF files, and allow more efficient storage of genotypes in multisample VCF files. For example, it is helpful and makes sense for a researcher to store all
genotypes for a single family in a single VCF file; however, the researcher may have interest in
performing set operations across multiple families (VCF files), such as performing an
intersection of variants from all affected individuals from all families.
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VTC has several operation-specific settings for intersects and complements that allow
researchers to specify genotype-level requirements. For intersects, VTC currently has five
genotype-level intersect methods and two record-level (i.e., ignore genotypes) intersect methods.
The genotype-level intersect methods are as follows: (1) heterozygous; (2) homozygous variant;
(3) heterozygous or homozygous variant; (4) homozygous reference; and (5) match sample
exactly across variant pools. The record-level intersect methods are: (1) variant; and (2) position.
The genotype-level intersect methods require that all sample genotypes involved in the
intersect fall into the specified category. One caveat is that the heterozygous genotype requires
the sample to have a reference allele. So if a sample’s genotype has two different variant alleles
(i.e. a tri-allelic position), though technically a heterozygote, will not be considered as such. This
distinction is made assuming that researchers interested in identifying heterozygotes will assume
the samples have a reference allele. This also greatly simplifies several corner cases when
dealing with multiple variants at a single location.
The record-level intersect methods ignore genotypes and only consider whether the
variant pools included in the analysis contain the variant. The “position” method only considers
chromosome, position, and the reference allele, while the “variant” method also includes the
alternate allele(s). For the “variant” method, records with multiple alternates are considered to
intersect if at least one of the alternates matches.
There are currently three complement methods: (1) heterozygous or homozygous variant;
(2) exact genotype matches; and (3) variant. When performing a complement, the “heterozygous
or homozygous variant” method requires that all sample genotypes in both variant pool be either
a heterozygous or homozygous variant in order to be removed from the variant pool being
subtracted from. The “exact genotype” method requires that all samples across both variant pools
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have the same genotype, whatever it may be. The “variant” method ignores genotypes and only
subtracts if the chromosome, position, reference, and alternate match between the two variant
pools.
Unions combine all variants and specified samples into a single VCF file regardless of
genotype. Samples missing variants will have a “no call” genotype (“./.”).
Detailed set operation syntax. The Set Operator tool in the VTC empowers researchers to
define set operations with a powerful, simple syntax. This simple syntax has several advantages:
(1) researchers may specify any number of input files (variant pools) to perform operations; (2)
researchers may specify specific samples within a given variant pool to include in the operation;
and (3) each operation is assigned an identification value (ID) automatically by VTC or specified
by the user, so that it can be used in subsequent operations. The general syntax structure for a
single operation is as follows (no spaces):
oId=operator[input_id1[sample_id1,sample_id2,etc.]:input_id2[sample_id3,sample_id4,etc.]:etc.]

where oId is a user-specified ID for the operation (may be omitted), operator is the operation of
interest (i, c, or u for intersect, complement, or union), input_id is the variant pool ID, and
sample_id is a sample ID for a sample within the given variant pool. If sample IDs are omitted,
Set Operator will use all samples within the variant pool. For example, the following intersect
operation will perform an intersect on all samples within the variant pools named “file1” and
“file2”: myOP=i[file1:file2].
Operation stringing. As previously mentioned, the set operation syntax allows resulting
variant pools to be used in subsequent operations. This feature allows researchers to obtain final
results with a single command in most circumstances. Continuing with the previous example,
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“myOP” may be specified in a subsequent operation as follows: “myOP=i[file1:file2]
myOP2=c[myOP:file3]”.
Intermediate files. When performing complex set operations, researchers may want all
intermediate operation results to be printed to a file. Otherwise, the researcher would be required
to perform separate commands. As such, a simple option named “--intermediate-files” will print
each operation result to a file named according to the specified “oId” previously mentioned.
Header repair. VCF files can be complex, and maintaining a valid VCF header can be
challenging. Since VTC is built on the code that defines VCFs, it is possible to detect invalid
VCF headers and repair them. VTC will automatically add missing required header information
such as the “GT” header line when genotypes are being printed. There are many useful
(unrequired) header lines that cannot be anticipated, however. This feature is still under active
development.
Add/remove “chr.” Chromosome numbers in VCF files may be prefixed by “chr” or may
simply be the chromosome ID (e.g., chrX or X). Many next-generation sequencing softwares are
incapable of handling VCF files that do not use the same convention simultaneously. For
example, if one file includes “chr” and another does not, current tools will reject the files. And
some tools require the VCF files to have the same chromosome ID as the reference sequenced
used in the original analysis. VTC will either prepend or remove “chr” from all variant records
seamlessly according to the user’s specifications by simply including (or omitting) the “--addchr” flag.
Summary information. Several tools exist that will provide high- or low-level detail on a
variant pool, but they can be cumbersome. VTC has a tool named VarStats that will provide a
quick summary of the variant pool, or a detailed variant-by-variant summary. High-level
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summary metrics include total number of variants, total number of single nucleotide variants
(SNVs), insertions and deletions, structural variants, and variants with multiple alternates. The
summary also includes summary depth and quality values. The variant-by-variant summary
includes allelic counts and the minimum, maximum, and average read depth and quality scores
for each variant.
Compare operation. Many analyses require researchers to perform several set operations
to identify all variants in common between VCFs, those that are unique to a given VCF, and
researchers may also need the combined set. Researchers are generally not satisfied knowing
only the number of variants that fall into each group, such as would be represented by a Venn
diagram. To obtain all of this information a researcher would perform four set operations: an
intersect (common variants), two complements (unique variants), and a union (combined set).
Set Operator has a compare operation (“--compare”) that will automatically perform all four
operations, print the results to their respective files, and print a summary of each resulting variant
pool to the console. This option currently is limited to two input files.
VCF association analysis. Association analyses are common using genomic data, but we
are not aware of any available tools to perform such analyses on VCF files. The VarStats tool in
VTC will perform association analyses on all variants in a variant pool if a phenotype file is
provided. Results, including odds ratios and p-values for each variant are printed to a file. If
there are multiple alternates at a given location, VarStats will perform the analysis on each
alternate and print results on a separate line. This option does not currently provide p-value
correction such as multiple test correction, but will be implemented in a future release. These
corrections can be easily performed in statistical software.

52

Future Directions
Filter tool. Next-generation sequencing variants are often filtered on various values
including quality scores and depth. Several tools already exist that, when combined, satisfy most
needs for filtering variants. Ideally, a single tool would incorporate all of this functionality along
with new features for simplicity.
File formats. While VCFs are the most common format for next-generation sequencing
variants, there are other file formats that will be incorporated into VTC including Plink (ped/map
or bim/bam/fam) and comma-separated value (CSV) files. Plink is particularly important since
there are many existing large-datasets in Plink format. In order to compare or combine data in
Plink format to those in VCF format, there must be a tool to handle this. VTC will enable
researchers to read in variant data from multiple formats and perform all of the same analyses
seamlessly. This is especially pertinent as a common QC measure of single nucleotide variants
identified in NGS studies is to compare NGS variants to variants genotyped on a SNP array.
Array data is most often reported in Plink format.
Enhanced compare. As different technologies are compared, there is a need to
determine concordance between samples tested on multiple technologies. VTC will implement
an “Enhanced Compare” option that will report genotypes that are perfect matches, imperfect
matches (heterozygous variant observed on one technology and homozygous variant observed
from the other), and no matches for the same samples on different technologies.
Additional SetOperator options. Anticipating all possible uses and hypotheses is
difficult with any new tool, especially with data as complex as genomic variants. Responding to
these needs is important and will likely involve updated SetOperator options. A few options we
plan to implement are to accommodate specialized union operations, similar to those for intersect
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and complement. Specifically, users may need to union only heterozygotes, heterozygotes or
homozygous variant, only homozygous variant, or only homozygous reference.
Incorporate new and existing tools. Building useful computational tools that interface
well together benefits researchers across all disciplines. New tools, while generally valuable to
the research community, often do not integrate well with other tools used within a discipline,
causing end users grief. There are likely many reasons for this fragmentation, but we would like
to address two major sources: (1) contributing to an existing project can be costly (in time and
money) and difficult; and (2) computational researchers need to publish their work to
demonstrate academic productivity.
While object-oriented programming mitigates much of the difficulty, contributing to an
existing project is still difficult because of the time and effort required to become familiar with
existing source code. Many projects have hundreds of classes with complex interactions that
make adding new functionality daunting. In many cases, a researcher may opt to write a separate
tool simply because it is more feasible. Unfortunately, this causes fragmentation between tools.
To promote well-integrated tools, VTC was written specifically to facilitate contribution with its
easily extensible code structure. Any computational researcher can begin a new tool without
needing to familiarize him/herself with other complex code.
Contributing to existing source code can be challenging, but publishing requirements also
present a challenge to computational researchers, since publications are an essential measure of
academic productivity. If a computational researcher adds a novel algorithm to an existing tool,
s/he may forfeit the opportunity to publish the algorithm and get feedback from the community.
Because VTC is simply a collection of useful tools, however, researchers can contribute an
independent tool or algorithm with an independent name and publish it independently.
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As we mentioned above, it is not possible to predict all possible operations and uses for
software like VTC and we anticipate the need for additional functionality. To this end, we invite
all computational researchers to contribute independent tools associated with variant analysis to
VTC. This will benefit researchers by promoting tool integration within a simple, intuitive
framework.
Conclusions
VCF files are the standard format for storing variants identified in next-generation
sequencing (NGS) and other studies, but working with them can be challenging. In this
manuscript we describe a novel program, the Variant Tool Chest (VTC). The Variant Tool Chest
is easily extendable and complements existing softwares by extending their capabilities without
replicating existing solutions for working with VCF files. VTC is available at
https://github.com/mebbert/VariantToolChest
Methods
Variant tool chest overview. The Variant Tool Chest (VTC) is a collection of tools to
analyze variants from next-generation sequencing (NGS) and other studies, and is intended to
become a tool chest to accommodate most analysis needs. It is written in Java (version 1.7) for
speed and portability. Two tools currently exist in the tool chest named SetOperator and
VarStats. Set Operator performs set operations such as intersects, complements, and unions on
variant sets termed variant pools. VarStats performs statistical operations including association
analyses and summaries on variant pools. Since there are numerous other tools necessary for
analyzing variant pools, VTC was written with an emphasis on extensibility.
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Extensibility. To make VTC easily extensible, each tool is written independently and is
self-contained within a single Java package. Researchers can add tools without being forced to
familiarize and integrate with other complicated code. A single class named VTCEngine is the
main entry for all tools. VTCEngine receives user input and executes the appropriate tool(s).
Most arguments are passed to, and handled by the tool of interest. Each tool uses a simple
argument-parsing library named Argparse4j [5] to define and handle all arguments. All tools use
the same variant and sample data structures known as VariantPool and SamplePool, respectively.
VariantPool is built on the open source public application programming interfaces (APIs)
distributed by the Broad Institute that define the Variant Call Format (VCF) file structure.
Specifically, the VTC is built on the Picard [6], SAMTools [7], tribble, and variant APIs. Tribble
provides necessary utilities for creating and working with various data file types, including VCF
indexes. All three libraries are essential components incorporated into the Genome Analysis
Toolkit (GATK) [3, 4]. As such, VTC is capable of reading and writing valid VCF files,
dependably. For generalizability, data structure classes are contained within the main
vtc.datastructures Java package. Any future classes generally applicable across multiple tools
should also be defined within the vtc.datastructures package. Likewise, a class named UtilityBelt
was created for methods that are generally applicable. The file structure of VTC can be seen in
Figure 3.1.
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Figure 3.1. Variant tool chest (VTC). The VTC was built to be extensible. Each new tool only
needs to interface with a few simple classes and is otherwise completely independent. All tools
should be self-contained within a single parent Java package. The main driver class for VTC is
VTCEngine. Any new tool should have its own Engine class and be instantiated from
VTCEngine. All generally applicable data structures such as VariantPool and SamplePool are
placed within the vtc.datastructure Java package. Any new generally applicable data structures
should also be placed in vtc.datastructure. Otherwise the data structure should be housed within
the tool’s package. Likewise, any generally applicable methods should be placed in the
UtilityBelt class.
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Abstract
Background. Ebbert et al. recently reported two potential gene-gene interactions
between rs11136000 (CLU) and rs670139 (MS4A4E) (SF=3.81, p=.016), and rs3865444 (CD33)
and rs670139 (MS4A4E) (SF=5.31, p=.003) using the Cache County data. Here, we evaluate
those interactions in a large, independent dataset.
Methods. Using 32 independent data sets from the Alzheimer’s Disease Genetics
Consortium (ADGC), we tested each interaction, controlling for age, gender, and APOE ε4 dose.
We then performed two meta-analyses per interaction (ADGC only and with Cache) using
METAL, and performed 10,000 permutations to obtain empirical p-values. We repeated the
meta-analyses in APOE ε4 carrier and non-carrier strata, estimated the combined population
attributable fraction (cPAF) for both, and explored causal variants.
Results. Our results support the CLU-MS4A4E interaction (ADGC: SF=2.37, p=0.007;
with Cache: SF=2.71, p=0.0004) and found a potential dosage effect using the ADGC data
between rs11136000:C/C and rs670139:G/T (with Cache: SF=1.73, p=0.02). Empirical p-values
obtained from permutations support the main interaction (ADGC: p=0.03; with Cache: p=0.002).
The CD33-MS4A4E interaction did not replicate (ADGC: SF=1.16, p=0.78). We found an
association for the CLU-MS4A4E interaction in Cache County for APOE ε4 negative individuals
(SF=4.75, p=0.005). This association only replicates including Cache (ADGC: SF=1.28, p=0.15;
with Cache: SF=2.08, p=0.004). The estimated cPAF for CLU and MS4A4E is 8.0. We found no
obvious causal variants.
Conclusions. We replicated the main CLU-MS4A4E interaction and provide evidence of
a possible dosage and APOE ε4 effect. We also estimate an 8% decrease in Alzheimer’s disease
incidence if the CLU-MS4A4E risk alleles were removed from the population.
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Introduction
Alzheimer’s disease (AD) is a common and complex neurodegenerative disease. It is the
most common cause of dementia and is characterized by the accumulation of amyloid plaques
and neurofibrillary tangles. To date, many genetic loci have been found that modify AD risk, but
collectively, they explain only a fraction of the heritability of the disease (1) and are not
diagnostically useful (2). It is hypothesized that rare variants with large effects as well as
epistatic interactions account for much of the unexplained heritability in AD and have been
largely hidden due to limitations in traditional GWAS studies. As such, rare variant and epistatic
effects are poorly understood. Recent studies, however, have demonstrated that gene-gene
interactions play a critical role in the etiology and progression of AD (2–5).
A recent study by Ebbert et al. (2) found evidence of two gene-gene interactions among
three known AD genes that increase AD risk: CLU-MS4A4E and CD33-MS4A4E. Specifically,
Ebbert et al. reported interactions between rs11136000 C/C (CLU) and rs670139 G/G (MS4A4E)
genotypes (synergy factor = 3.81; p = .016), and the rs3865444 C/C (CD33) and rs670139 G/G
(MS4A4E) genotypes (synergy factor = 5.31; p = .003). All three genes are on the “AlzGene Top
Results” list, which summarizes the most established genes associated with AD to date.
In this study, we attempted to replicate these gene-gene interactions by performing an
independent meta-analysis of data sets from the Alzheimer’s Disease Genetics Consortium
(ADGC), followed by a combined meta-analysis including the original Cache County data. We
also tested for dosage effects in both interactions and an APOE ε4 effect. We then performed a
rigorous permutation experiment to test robustness of results that had a significant p-value in the
independent analysis. We also explored possible causal variants using whole-genome sequence
data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The main CLU-MS4A4E
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interaction replicates in both the independent and combined meta-analysis, with minor evidence
of a dosage effect. There is also minor evidence of an association between the CLU-MS4A4E
interaction and case-control status in APOE ε4 negative individuals. The CD33-MS4A4E
interaction failed to replicate.
Methods
SNP data preparation and statistical analysis. We used SNP microarray data from
ADGC in this study, which consists of 32 studies over two phases. More information about this
dataset can be found in a previous report by Naj et al. (6) and the ADGC data preparation
description (7).
Since gene-gene interactions are challenging to identify and replicate, we used only the
highest quality data possible. For each ADGC data set, we filtered SNPs imputed with low
information (info < .5) and then converted the IMPUTE2/SNPTEST format files to PLINK
format, using PLINK v1.90b2i (8). We used the default PLINK uncertainty cutoff of .1, meaning
any imputed call with uncertainty greater than .1 was treated as missing. We included SNPs with
a missing genotype rate less than 0.05 (PLINK command ‘--geno 0.05’). After cleaning SNPs,
we included only individuals with a missing rate less than 0.01 (PLINK option ‘--mind 0.1’) to
select only the samples with high genotyping rates. We then extracted the three SNPs of interest:
rs3865444 (CD33), rs670139 (MS4A4E), and rs11136000 (CLU) and tested Hardy-Weinberg
equilibrium (9; 10). Using R v3.1.1 (11), we then excluded all samples that did not have
complete data for all covariates including age, gender, cohort, case-control status, APOE ε4 dose,
and the two SNPs being tested in the corresponding interaction. Any data sets missing the
respective SNPs or covariates after data cleaning were excluded from further analysis.
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Following data preparation, we tested the individual interactions in each data set using
logistic regression. We performed logistic regressions in R using the covariates previously
mentioned. We defined the R models as “case_control ~ rs3865444*rs670139 + apoe4dose + age
+ sex” and “case_control ~ rs11136000*rs670139 + apoe4dose + age + sex” for the CD33MS4A4E and CLU-MS4A4E interactions, respectively, which include the main and interaction
effects in the models. All analyses in this study used each gene’s homozygous minor allele as the
reference group.
Using results from each study, we performed a meta-analysis to test significance across
the ADGC data sets using the METAL version released on 2011-03-25 (12), and performed a
second meta-analysis including the Cache County results. We tested the originally reported
interactions, along with heterozygous interactions (rs11136000 C/C interacting with rs670139
G/T and rs3865444 C/C interacting with rs670139 G/T) to check for potential dosage effects,
based on suggestive evidence found in the original Cache County study (Supplemental Table
4.1). We also stratified the Cache County data by APOE ε4 status and tested for an association
with case-control status. Based on those results, we then tested for the same association in the
ADGC data.
Following the meta-analyses, we performed a permutation analysis with 10,000
permutations for interactions that replicated in the independent data set. For each ADGC data set,
we randomly permuted case-control status across all individuals, tested the interaction by logistic
regression, and reran the meta-analysis. We stored the p-values from each of the 10,000 metaanalyses. We then calculated the empirical p-value by finding the original p-value’s rank in the
distribution of p-values divided by the number of permutations.
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Our results are represented as synergy factors (4; 13) and their associated 95%
confidence intervals and p-values. Synergy factors measure whether the effect size of two
interacting genetic variants is greater than the sum. Similar to odds ratios, synergy factors less
than one and greater than one suggest decreased and increased risk in case-control studies,
respectively, as long as the appropriate reference group is used.
We calculated each synergy factor’s 95% confidence interval for each meta-analysis, but
omitted the ADC1 cohort, which had only a single case, inclusion of which made the 95%
confidence interval for the summary synergy factor from 0 - ∞.
Exploring causal mutations. We explored causal mutations for confirmed interactions
using 809 ADNI whole genomes that were sequenced, aligned to hg19, and variants called by
Illumina using their internal analysis procedure. We used linkage disequilibrium, Regulome DB
(accessed November 2014) (14), and functional annotations from wAnnovar (15) to isolate SNPs
of interest. We first extracted all SNPs within approximately 50 kilobases of each SNP of
interest, calculated linkage disequilibrium using Haploview (16), and retained all SNPs with a D’
≥ 0.99. Using Regulome DB and wAnnovar, we annotated each remaining SNP for: (1) known
regulation and functional effects; (2) minor allele frequencies from the 1000 Genomes Project
(17), 6500 Exomes Project (18), and the ADNI data set; and (3) corresponding MutationTaster
predictions (19). We retained all SNPs with a Regulome DB score less than 4, and all SNPs
located in untranslated (UTRs) or exonic regions (if nonsynonymous). For each retained SNP,
we tested individual associations with case-control status and subsequently tested their
interaction with all SNPs in the other interacting gene.
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Results
Sample and data set demographics. Sample demographics and minor allele frequencies
for each SNP are presented for each data set (Table 4.1). Nine of the 32 data sets passed quality
controls for the CD33-MS4A4E interaction while seven passed for CLU-MS4A4E. The remaining
data sets were either missing required SNP(s), missing a covariate, or consisted of only controls
and could not be included in the analysis. All SNPs passed Hardy-Weinberg equilibrium in all
data sets for both cases and controls.
Interaction and dosage meta-analysis results. The originally reported CLU-MS4A4E
interaction between the rs11136000 C/C (CLU) and rs670139 G/G (MS4A4E) genotypes
replicates in both the independent (synergy factor = 2.37, p = 0.007; Figure 4.1b) and combined
(synergy factor = 2.71, p = 0.0004; Figure 4.1b) meta-analyses (Supplemental Table 4.1), with
minor evidence for a dosage effect in the combined meta-analysis (synergy factor = 1.73, p =
0.02; Figure 4.1a). Empirical p-values obtained from permutations support the main interaction
(ADGC: p = 0.03; with Cache: p = 0.002). We found an association with case-control status in
people with no APOE ε4 alleles in the Cache County data alone (synergy factor = 4.75, p =
0.005; Supplemental Table 4.2) that did not exist in people with one or more APOE ε4 alleles
(synergy factor = 1.22, p = 0.74; Figure 4.2b; Supplemental Table 4.2). The association in APOE
ε4 negative subjects did not replicate in the meta-analysis across the ADGC (synergy factor =
1.28, p = 0.15; Figure 4.2b; Supplemental Table 4.2), though it was significant when including
the Cache County data (synergy factor = 2.08, p = 0.004; Figure 4.2b; Supplemental Table 4.2).
The CD33-MS4A4E interaction failed to replicate in either the independent (synergy factor =
1.16, p = 0.78; Figures 4.3a and 4.3b) or combined (synergy factor = 1.63, p = 0.24; Figures 4.3a
and 4.3b) meta-analyses.
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Table 4.1. Sample Demographics by Data Set
Study

N

Cases (%)

Females (%)

Age

APOE 4 + (%)

ACT1
ADC1
ADC2
ADNI
LOAD
TARC1
UMVUMSSM_A
UMVUMSSM_B
UMVUMSSM_C

1858
388
681
371
2965
388
1058
390
271

487 (26.2)
1 (00.3)
566 (83.1)
230 (62.0)
1515 (51.1)
244 (62.9)
450 (42.5)
135 (34.6)
210 (77.5)

1068 (57.5)
237 (61.1)
365 (53.6)
157 (42.3)
1882 (63.5)
244 (62.9)
676 (63.9)
236 (60.5)
160 (59.0)

82.28
74.99
79.38
77.82
78.22
78.96
75.48
73.99
74.77

526 (28.3)
129 (33.2)
394 (57.9)
201 (54.2)
1667 (56.2)
189 (48.7)
451 (42.6)
118 (30.3)
167 (61.6)

rs670139 MAF rs3865444 MAF
(T)
(A)
0.41
0.41
0.42
0.45
0.43
0.43
0.43
0.41
0.42

0.33
0.33
0.33
0.31
0.31
0.32
0.31
0.33
0.29

rs11136000 MAF
(T)
NA
0.39
0.39
0.37
0.38
0.41
0.38
0.38
NA

Note. For each dataset the following information is provided: percent cases and females, age, APOE ε4 positive percentage, and minor allele frequencies for
rs670139, rs3865444, and rs11136000.
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Figure 4.1a. Forest plot showing CLU-MS4A4E interaction replication with potential
dosage effect: Original interaction test. We tested the original interaction, which replicated in
both the independent and combined meta-analyses (figure b). We also tested for a dosage effect,
which did not replicate independently, but does in the combined (figure a). The ADC1 data set
was omitted when calculating the 95% confidence interval for the meta-analysis synergy factor
because the data set only had 1 case, giving a standard error from 0 - ∞.
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Figure 4.1b. Forest plot showing CLU-MS4A4E interaction replication with potential
dosage effect: Dosage effect test. We tested the original interaction, which replicated in both the
independent and combined meta-analyses (figure b). We also tested for a dosage effect, which
did not replicate independently, but does in the combined (figure a). The ADC1 data set was
omitted when calculating the 95% confidence interval for the meta-analysis synergy factor
because the data set only had 1 case, giving a standard error from 0 - ∞.
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Figure 4.2a. Forest plot showing APOE ε4 negative association with Alzheimer’s disease
case-control status: Independent meta-analysis. We stratified the Cache County data by
APOE ε4 status and tested for an association with Alzheimer’s disease case-control status. We
found an association in the APOE ε4 negative stratum in Cache County that did not replicate in
the independent meta-analysis, but did in the combined analysis (figure b). There was no
association in the APOE ε4 positive stratum.
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Figure 4.2b. Forest plot showing APOE ε4 negative association with Alzheimer’s disease
case-control status: Combined analysis. We stratified the Cache County data by APOE ε4
status and tested for an association with Alzheimer’s disease case-control status. We found an
association in the APOE ε4 negative stratum in Cache County that did not replicate in the
independent meta-analysis, but did in the combined analysis (figure b). There was no association
in the APOE ε4 positive stratum.
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Figure 4.3a. Forest plot showing CD33-MS4A4E failed replication of interaction and dosage
effect: Independent meta-analysis. We tested the original interaction, which did not replicate in
either the independent or combined meta-analyses (figure b). We also tested for a dosage effect,
which also did not exist. The ADC1 data set was omitted when calculating the 95% confidence
interval for the meta-analysis synergy factor because the data set only had 1 case, giving a
standard error from 0 - ∞.
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Figure 4.3b. Forest plot showing CD33-MS4A4E failed replication of interaction and
dosage effect: Combined analysis. We tested the original interaction, which did not replicate in
either the independent or combined meta-analyses (figure b). We also tested for a dosage effect,
which also did not exist. The ADC1 data set was omitted when calculating the 95% confidence
interval for the meta-analysis synergy factor because the data set only had 1 case, giving a
standard error from 0 - ∞.
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Exploring causal mutations. Since only the CLU-MS4A4E interaction replicated, we
only explored causal SNPs within these genes. There were 36 and 32 SNPs that fit the inclusion
criteria previously described for SNPs in the regions of rs11136000 and rs670139, respectively
(Supplemental Tables 4.3 and 4.4). Most of the SNPs are rare (MAF < 0.01) according to the
1000 Genomes, 6500 Exomes, and ADNI data sets. None of the SNPs were significantly
associated with case-control status individually. The pairwise interaction association tests
between all included SNPs near and including rs11136000 (CLU) and rs670139 (MS4A4E)
revealed an interaction between rs670139 and rs1532278 (synergy factor = 1.83, p = 0.01
unadjusted). The SNP rs1532278 was previously identified by Naj et al. (6) as being associated
with case-control status. There were three suggestive interactions between rs9331931 (CLU,
intronic) and the following: (1) rs7926344 (synergy factor = 0.53, p = 0.06); (2) rs2081547
(synergy factor = 0.53, p = 0.06); and (3) rs11230180 (synergy factor = 0.54, p = 0.07). SNPs
rs2081547 and rs11230180 are interesting because they have been shown to modify expression
of MS4A4A (20), the gene upstream from MS4A4E. They also have a Regulome DB score of
‘1f’, meaning they are known to modify expression and are known DNase and transcription
factor binding sites.
Discussion
In this study we attempted to replicate two gene-gene interactions and their association
with Alzheimer’s disease case-control status. The CD33-MS4A4E interaction failed to replicate,
and may have resulted from over-fitting in the Cache County data. The CD33 protein interacts
indirectly with a protein related to MS4A4E known as MS4A2 by physically interacting with the
CBL protein that interacts with MS4A2. Both MS4A4E and MS4A2 are members of the
membrane-spanning 4-domain gene family, giving credence to an interaction between CD33 and
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MS4A4E. Statistical evidence for this interaction is lacking, however, and more analyses may be
necessary to draw more definitive conclusions.
We replicated the CLU-MS4A4E interaction, and further demonstrated some evidence of
a dosage effect for MS4A4E along with a potential association in APOE ε4 negative subjects. The
interaction between the rs11136000 (CLU) C/C and rs670139 (MS4A4E) G/G genotypes is
significant in both the independent meta-analysis (synergy factor = 2.37, p = 0.007) using only
the ADGC data sets and the combined meta-analysis (synergy factor = 2.71, p = 0.0004)
including the Cache County data, suggesting it may be valid. There is, however, a distinction to
be made regarding statistical epistasis and biological epistasis. While there is evidence that CLU,
like CD33, interacts indirectly with MS4A2, little is known about MS4A4E itself and we do not
know whether it biologically interacts with CLU. MS4A2 indirectly modifies BCL2L1 activation
or expression (2), which physically interacts with CLU. Research suggests CLU prevents
amyloid fibrils and other protein aggregation events (Yerbury et al 2007) while MS4A4E may
facilitate aggregation as a membrane-spanning protein. Membrane-spanning proteins play
diverse roles in cell activity including transport and signaling. Experiments will be required to
determine whether there is biological epistasis between CLU and MS4A4E, and whether the
interaction affects amyloid fibril formation. These results indicate further investigative efforts in
gene-gene interactions (and protein-protein interactions) may be important to resolve
Alzheimer’s disease etiology.
We tested for evidence of an APOE ε4 effect in the Cache County data and found a
significant effect in APOE ε4 negative subjects and no significant effect in APOE ε4 positive
subjects. Subsequent meta-analyses with the ADGC data suggest this effect may be valid, though
it only replicates when including the original Cache County result.
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Since all analyses in this study used each gene’s homozygous minor allele as the
reference group, the interactions between major alleles are framed as a risk factor, meaning the
interaction between the minor alleles is protective. The minor allele for CLU is protective as is
being APOE ε4 negative, while the minor allele for MS4A4E increases risk. The interaction
between CLU and MS4A4E from the minor allele perspective is protective.
We found no obvious causal variants linked to rs11136000 or rs670139 with a D’ ≥ 0.99
in the ADNI whole-genome data, though we believe further analysis of both rs11230180
(MS4A4E) and rs2081547 (MS4A4E) are warranted given their known expression effect on
MS4A4A. SNP rs9331931 (CLU) has minimal regulome evidence, but is also worth further
investigation.
A major gap in Alzheimer’s disease literature to date is the lack of known causal variants.
Several SNPs have repeatedly turned up in genome-wide association studies, but the tagSNPs
themselves are unlikely to play a direct role in Alzheimer’s disease etiology. What is more likely
is that the tagSNPs are in close linkage disequilibrium with one or more causal variants. We
believe there are two explanations: (1) the SNPs are linked to multiple rare variants that drive
Alzheimer’s disease development and progression; or (2) there is another common variant in the
region with functional effects that remain unknown. In either case, given the biological
complexity of Alzheimer’s disease and results presented in this study, we believe epistasis plays
a critical role in Alzheimer’s disease etiology. As such, the community must continue to identify
and vet these and other interactions that are supported in the literature.
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Supplemental Table 4.1. Independent and Combined Meta-Analyses Replicate CLU-MS4A4E Interaction, but CD33-MS4A4E
Fails to Replicate
Gene interaction (rs)
CLU:MS4A4E (rs11136000:rs670139)

CD33:MS4A4E (rs3865444:rs670139)

Genotype

Study (direction)

Synergy factor (95%
CI)

p-value

N

CC:GT

ADC1 (-)
ADC2 (-)
ADNI (+)
LOAD (+)
TARC1 (-)
UMVUMSSM_a (+)
UMVUMSSM_b (-)
Cache County (+)
Meta (no Cache)
Meta (with Cache)

0.23 (0 - ∞)
0.50 (0.06 - 4.42)
2.40 (0.30 - 19.19)
2.11 (0.98 - 4.55)
0.33 (0.04 - 2.80)
3.03 (0.92 - 9.93)
0.70 (0.07 - 7.34)
2.98 (1.003 - 8.86)
1.40 (0 - ∞)
1.73 (0 - ∞)

0.50
0.27
0.20
0.03
0.16
0.03
0.38
0.05
0.11
0.02

388
681
371
2965
395
1067
390
2419
6257
8676

CC:GG

ADC1 (+)
ADC2 (+)
ADNI (+)
LOAD (+)
TARC1 (-)
UMVUMSSM_a (+)
UMVUMSSM_b (+)
Cache County (+)
Meta (no Cache)
Meta (with Cache)

170.82 (0 - ∞)
1.07 (0.13 - 8.83)
2.81 (0.30 - 25.70)
1.90 (0.83 - 4.35)
0.39 (0.05 - 3.30)
2.57 (0.67 - 9.83)
3.16 (0.27 - 36.74)
3.81 (1.28 - 11.32)
2.37 (0 - ∞)
2.71 (0 - ∞)

0.50
0.47
0.18
0.07
0.19
0.08
0.18
0.02
0.007
0.0004

388
681
371
2965
395
1067
390
2419
6257
8676

CC:GT

ACT1 (-)
ADC1 (+)
ADC2 (+)
ADNI (+)
LOAD (+)
TARC1 (-)
UMVUMSSM_a (+)
UMVUMSSM_b (-)
UMVUMSSM_c (-)

0.62 (0.20 - 1.90)
21.23 (0 - ∞)
2.01 (0.16 - 25.46)
7.34 (0.49 - 109.57)
1.02 (0.40 - 2.60)
0.28 (0.02 - 5.14)
1.53 (0.37 - 6.37)
0.89 (0.02 - 42.43)
0.72 (0.02 - 23.49)

0.20
0.50
0.30
0.07
0.48
0.20
0.28
0.48
0.43

1858
388
681
371
2965
388
1058
390
271
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Gene interaction (rs)

Genotype

Study (direction)
Cache County (+)
Meta (no Cache)
Meta (with Cache)

CC:GG

ACT1 (-)
ADC1 (+)
ADC2 (+)
ADNI (+)
LOAD (-)
TARC1 (+)
UMVUMSSM_a (+)
UMVUMSSM_b (-)
UMVUMSSM_c (-)
Cache County (+)
Meta (no Cache)
Meta (with Cache)

Synergy factor (95%
CI)

p-value

N

1.70 (0.63 - 4.58)
1.18 (0 - ∞)
1.28 (0 - ∞)

0.30
0.65
0.37

2419
8370
10789

0.90 (0.28 - 2.93)
90.09 (0 - ∞)
1.76 (0.13 - 23.77)
8.00 (0.43 - 148.42)
0.66 (0.24 - 1.78)
1.27 (0.05 - 30.14)
1.11 (0.26 - 4.69)
0.59 (0.01 - 29.50)
0.41 (0.01 - 19.21)
5.31 (1.79 - 15.77)
1.16 (0 - ∞)
1.63 (0 - ∞)

0.43
0.50
0.33
0.08
0.21
0.44
0.44
0.40
0.32
0.003
0.78
0.24

1858
388
681
371
2965
388
1058
390
271
2419
8370
10789

Note. Logistic regression results from each data set and both meta-analyses are shown for the main CLU-MS4A4E and CD33-MS4A4E interactions and their
respective dosage analyses. The CLU-MS4A4E interaction replicates in both independent and combined meta-analyses. There is also evidence of a dosage effect
when including the Cache County data in the meta-analysis. The CD33-MS4A4E interaction fails to replicate.
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Supplemental Table 4.2. Minor Evidence of an Association with Alzheimer’s Disease CaseControl Status in APOE ε4 Negative Individuals

Study (direction)

Synergy
factor (95%
CI)

p-value

N

+

ADC1 (NA)
ADC2 (NA)
ADNI (NA)
LOAD (+)
TARC1 (-)
UMVUMSSM_a (+)
UMVUMSSM_b (+)
Cache County (+)
Meta (no Cache)
Meta (with Cache)

NA
NA
NA
1.20 (0.59 0.29 (0.03 1.82 (0.32 1.53 (0.06 1.22 (0.36 1.17 (0.62 1.19 (0.67 -

NA
NA
NA
0.31
0.16
0.25
0.40
0.74
0.26
0.26

129
394
201
1667
193
456
118
749
3158
3907

-

ADC1 (NA)
ADC2 (-)
ADNI (-)
LOAD (+)
TARC1 (+)
UMVUMSSM_a (+)
UMVUMSSM_b (+)
Cache County (+)
Meta (no Cache)
Meta (with Cache)

NA
0.48 (0.06 0.58 (0.04 1.18 (0.47 1.85 (0.31 2.63 (0.79 1.28 (0.18 4.75 (1.59 1.28 (0.70 2.08 (1.19 –

NA
0.25
0.35
0.37
0.25
0.06
0.41
0.005
0.15
0.004

259
287
170
1298
202
611
272
1670
3099
4769

APOE ε4 status

Note. We found a significant association between Alzheimer’s disease case-control status and APOE ε4 negative
individuals in the Cache County data set, while no association existed in APOE ε4 positive individuals. The
association in APOE ε4 negative individuals did not replicate independently, but was significant when including the
Cache County data in the meta-analysis.
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Supplemental Table 4.3. Top Variants in Linkage Disequilibrium with rs11136000 (CLU) that Have a Regulome DB Score
Less than 4, or Are Located in UTR or Exonic Regions
Regulome
DB

Function

Function
consequence

MAF
(ADNI)

MAF
(1000G)

MAF
(esp6500)

0.001
0.014
0.007
0.006
0.006
0.001
0.62
0.001
0.001
0.003
0.001
0.02

0.004
0.004
0.05
0.003
0.004

0.06

SNP

SNP

Ref

Alt

Position

Gene

rs11136000
(CLU)

chr8:27441327
rs9331945
rs9331892
chr8:27445942
chr8:27449609
chr8:27452473
rs1532278
chr8:27468411
rs56121659
rs9331886
chr8:27471977
rs77336101

C
A
G
G
G
C
T
T
C
C
G
G

T
G
A
A
A
T
C
C
T
T
C
A

27441327
27454957
27468005
27445942
27449609
27452473
27466315
27468411
27469064
27469066
27471977
27474871

2a
2b
2b
2b
2b
2b
2b
2b
2b
2b
2b
2b

intergenic
UTR3
exonic
intergenic
intergenic
intergenic
intronic
intronic
intronic
intronic
intronic
intergenic

chr8:27475208

C

G

27475208

2b

intergenic

0.002

0.0005

rs73560231

C

T

27478302

2b

intergenic

0.002

0.003

chr8:27491389
chr8:27494300
rs73679246
rs73558162
rs78590228
chr8:27445866
chr8:27448407
chr8:27452662
rs9331931
chr8:27461286
chr8:27483098

G
G
G
G
G
C
A
A
G
C
C

A
C
A
A
T
T
G
G
C
A
T

27491389
27494300
27463156
27423389
27442119
27445866
27448407
27452662
27458104
27461286
27483098

2b
2b
2c
3a
3a
3a
3a
3a
3a
3a
3a

upstream
intronic
intronic
intergenic
intergenic
intergenic
intergenic
intergenic
intronic
intronic
intergenic

0.002
0.001
0.009
0.001
0.001
0.009
0.003
0.001
0.28
0.001
0.001

rs56276902
chr8:27472251
chr8:27491676
chr8:27507233

A
G
C
G

G
T
T
A

27511118
27472251
27491676
27507233

EPHX2, CLU
CLU
CLU
EPHX2, CLU
EPHX2, CLU
EPHX2, CLU
CLU
CLU
CLU
CLU
CLU
CLU,
SCARA3
CLU,
SCARA3
CLU,
SCARA3
SCARA3
SCARA3
CLU
EPHX2, CLU
EPHX2, CLU
EPHX2, CLU
EPHX2, CLU
EPHX2, CLU
CLU
CLU
CLU,
SCARA3
SCARA3
CLU
SCARA3
SCARA3

3a
4
4
5

intronic
UTR5
UTR5
exonic

0.002
0.003
0.001
0.001

0.003
0.0009

rs9331938

C

T

27457479

CLU

7

exonic

0.002

rs9331936

T

G

27457512

CLU

7

exonic

chr8:27462461

G

A

27462461

CLU

7

exonic
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synonymous

nonsynonymous
nonsynonymous
nonsynonymous
non-

Mutation taster
score
(prediction)

0.72
0.003
0.01
0.02
0.02

0.07
0.01
0.01
0.0009
0.0005
0.15

0.004

0.997 (N)

0.0002

0.881 (N)

0.005

0.01

1 (N)

0.008

0.06

0.07

0 (P)

0.001

0.0005

0.001

1 (N)

SNP

SNP

Ref

Alt

Position

Gene

Regulome
DB

rs41276297

G

A

27462662

CLU

7

exonic

chr8:27516016

C

T

27516016

SCARA3

7

exonic

chr8:27516732

C

T

27516732

SCARA3

7

exonic

rs3735754

G

A

27516955

SCARA3

7

exonic

Function

Function
consequence
synonymous
nonsynonymous
nonsynonymous
nonsynonymous
nonsynonymous

MAF
(ADNI)

MAF
(1000G)

MAF
(esp6500)

Mutation taster
score
(prediction)

0.001

0.001

0.003

1 (N)

0.001

1 (N)

0.001
0.002

0.04

0.00008

1 (D)

0.001

0.997 (D)

Note. Using the ADNI whole-genome data, we used linkage disequilibrium, Regulome DB (accessed November 2014), and functional annotations from
wAnnovar to isolate SNPs of interest. We first extracted all SNPs within approximately 50 kilobases of each SNP of interest, calculated linkage disequilibrium
using Haploview, and retained all SNPs with a D’ ≥ 0.99. Using Regulome DB and wAnnovar, we annotated each remaining SNP for: (1) known regulation and
functional effects; (2) minor allele frequencies from the 1000 Genomes Project, 6500 Exomes Project, and the ADNI data set; and (3) corresponding
MutationTaster predictions. We retained all SNPs with a Regulome DB score less than 4, and all SNPs located in untranslated (UTRs) or exonic regions (if
nonsynonymous). No SNPs were significantly associated with case-control status in the ADNI whole-genome data.
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Supplemental Table 4.4. Top Variants in Linkage Disequilibrium with rs670139 (MS4A4E) that Have a Regulome DB Score
Less than 4, or Are Located in UTR or Exonic Regions

SNP

SNP

Ref

Alt

Position

Gene

rs670139

rs11230180

G

T

59961486

(MS4A4E)

rs2081547

C

T

59989430

chr11:59940500

C

T

59940500

chr11:59936960

G

A

59936960

chr11:59961500

A

G

59961500

rs79917136

T

G

59961877

chr11:59962069

T

A

59962069

rs76834915

G

T

59936781

rs79315507

T

G

59923606

chr11:59926285

A

G

59926285

rs12285212

G

T

59927523

chr11:59929465

C

T

59929465

chr11:59936007

G

A

59936007

chr11:59936023

C

G

59936023

rs683892
chr11:59943683
chr11:59960287

A
C
C

T
T
T

59938266
59943683
59960287

chr11:59961597

G

T

59961597

rs7926344

G

A

59962166

rs71488445

T

C

59962240

chr11:59998347

A

T

59998347

MS4A6A,
AB231731
AB231729,
AB231731
MS4A6A,
MS4A6A
MS4A2,
MS4A6A
MS4A6A,
AB231731
MS4A6A,
AB231731
MS4A6A,
AB231731
MS4A2,
MS4A6A
MS4A2,
MS4A6A
MS4A2,
MS4A6A
MS4A2,
MS4A6A
MS4A2,
MS4A6A
MS4A2,
MS4A6A
MS4A2,
MS4A6A
MS4A6A
MS4A6A
MS4A6A,
AB231731
MS4A6A,
AB231731
MS4A6A,
AB231731
MS4A6A,
AB231731
AB231729,
AB231731

Regulome
DB

Function

1f

MAF
(ADNI)

MAF
(1000G)

intergenic

0.36

0.27

1f

ncRNA_intronic

0.37

0.31

2b

exonic;splicing

0.004

0.005

2b

intergenic

2b

intergenic

0.003

2b

intergenic

0.006

0.01

2b

intergenic

0.02

0.01

2c

intergenic

0.002

0.01

3a

intergenic

0.001

0.01

3a

intergenic

0.001

3a

intergenic

0.002

0.01

3a

intergenic

0.002

0.003

3a

intergenic

0.01

0.005

3a

intergenic

0.002

0.01

3a
3a
3a

downstream
intronic
intergenic

0.002
0.005
0.002

0.002

3a

intergenic

0.001

3a

intergenic

0.36

0.27

3a

intergenic

0.07

0.03

3a

upstream

0.002

0.01
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Function
consequence

nonsynonymous

0.001

MAF
(esp6500)

Mutation
taster score
(prediction)

0.003

0.996 (N)

SNP

Regulome
DB

Function

Function
consequence

MAF
(ADNI)

MAF
(1000G)

SNP

Ref

Alt

Position

Gene

chr11:60009095

C

T

60009095

3a

intergenic

0.003

chr11:59940217
chr11:59940271
chr11:59950687
chr11:59940074
chr11:59980590

A
A
C
G
C

T
C
G
A
T

59940217
59940271
59950687
59940074
59980590

4
4
4
5
5

UTR3
UTR3
UTR5
UTR3
ncRNA_exonic

0.002
0.002
0.002
0.002
0.006

0.01
0.004
0.004
0.0005

rs7929057

C

T

59980598

5

ncRNA_exonic

0.13

0.13

chr11:59980750

C

T

59980750

AB231731,
MS4A4A
MS4A6A
MS4A6A
MS4A6A
MS4A6A
AB231729,
AB231731
AB231729,
AB231731
MS4A4E

6

exonic

0.001

0.0005

chr11:59939123
chr11:59939286
rs61742546

C
T
A

T
C
G

59939123
59939286
59949058

MS4A6A
MS4A6A
MS4A6A

7
7
7

UTR3
UTR3
exonic

0.002
0.002
0.02

0.0005
0.004
0.01

nonsynonymous
nonsynonymous

MAF
(esp6500)

Mutation
taster score
(prediction)

1 (N)

0.02

1 (N)

Note. Using the ADNI whole-genome data, we used linkage disequilibrium, Regulome DB (accessed November 2014), and functional annotations from
wAnnovar to isolate SNPs of interest. We first extracted all SNPs within approximately 50 kilobases of each SNP of interest, calculated linkage disequilibrium
using Haploview, and retained all SNPs with a D’ ≥ 0.99. Using Regulome DB and wAnnovar, we annotated each remaining SNP for: (1) known regulation and
functional effects; (2) minor allele frequencies from the 1000 Genomes Project, 6500 Exomes Project, and the ADNI data set; and (3) corresponding
MutationTaster predictions. We retained all SNPs with a Regulome DB score less than 4, and all SNPs located in untranslated (UTRs) or exonic regions (if
nonsynonymous). No SNPs were significantly associated with case-control status in the ADNI whole-genome data.
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Chapter 5
Future Directions
Despite decades of research, a major gap in Alzheimer’s disease etiology persists, and no
effective treatments exist. A major contributor to this gap is the void of known causal variants, or
even a clear understanding of which pathways drive development and progression of
Alzheimer’s disease clinical symptoms. There are many avenues to pursue in understanding
Alzheimer’s disease, but discovering the genetic basis for the disease is a critical aspect that
researchers must accomplish to understand its etiology. Understanding the pleiotropic and
epistatic nature of involved genes, and specific mutations, may be critical. Several SNPs have
repeatedly turned up in genome-wide association studies, but the SNPs themselves generally do
not have obvious functional effects, and are unlikely to play a role in Alzheimer’s disease
etiology. What is more likely is that the SNPs are linked to one or more causal variants. We see
two possible reasons the non-causal SNPs are robust across data sets, yet causal variants remain
elusive: (1) the SNPs are linked to multiple rare variants that drive Alzheimer’s disease
development and progression; or (2) there is another common variant in the region that is either
unobserved in large studies, or has misunderstood functional effects (e.g., gene regulation).
Examples of common and rare functional variants with significant effects on Alzheimer’s disease
development and progression include the common APOE ε4 and APOE ε2 alleles, and the rare
TREM2 rs75932628 (R47H) variant and the PLD3 rs145999145 (V232M) variant. Whether the
causal variants are rare or common, given the biological complexity of Alzheimer’s disease and
results presented in this study, we believe epistasis plays a critical role in Alzheimer’s disease
etiology. As such, the community must continue to identify and vet these interactions.
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In this research, we identified an interaction between rs11136000 (CLU) and rs670139
(MS4A4E) in the Cache County data that later replicated in a meta-analysis across the ADGC
data. We also identified potential dosage and APOE ε4 effects. To further understand this
interaction’s nature, researchers need to do the following: (1) test the interaction in more data
sets to verify its veracity; (2) identify causal variants in the region; and (3) test causal variants in
vitro within cell lines or in vivo within mice.
Identifying and verifying epistatic interactions is challenging, largely because of the
statistical power limits. There are

𝑛𝑛(𝑛𝑛−1)
2

possible interactions amongst covariates, where 𝑛𝑛 is the

number of genotypes. Given the large number of variables that can be included, the number of
hypothesis tests grows quickly, draining valuable statistical power. Thus, managing false
positives and negatives becomes an uphill battle. Once an interaction is identified, testing
replication is still challenging because having data sets large enough to contain sufficient

numbers of each genotype is not trivial. The CLU-MS4A4E interaction we identified replicated in
ADGC, but epistatic interactions must be vetted to prevent costly, unsuccessful biological
experiments. With further evidence to support this interaction, future experiments to understand
the biological nature will be warranted.
Along with further replication, researchers need to identify causal variants in the region.
At present, the two most likely explanations are multiple rare causal variants linked with
rs11136000 and rs670139, and more common SNPs that weren’t measured in genome-wide
association data sets. Next-generation sequencing across large cohorts in these areas should
provide the necessary clarity to identify the causal variants, whether rare or common. We
identified a list of variants for both rs11136000 and rs670139 (Supplemental Tables 4.3 and 4.4)
with a D’ ≥ 0.99 using next-generation sequencing and annotated them with their known
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regulome and exonic functions. Most were rare variants with no known functional effect, but
some are worth investigating because of known function. Genotyping these alleles in a large
cohort such as the Cache County data will make it possible to explore association with
Alzheimer’s disease development.
Any vetted variants that demonstrate statistical verification and have reasonable
biological support need to be tested in vitro or in vivo to verify function. Research suggests CLU
prevents amyloid fibrils and other protein aggregation events. Any variants known to modify CLU
expression or function should be tested for correlation with protein aggregation in vitro. Little is known
about MS4A4E, but given the statistical interaction with CLU, testing suspect functional variants with
protein aggregation may be the most logical choice.

We have presented valuable information regarding epistasis in Alzheimer’s disease in
this research, including a novel gene-gene interaction between CLU and MS4A4E that modulates
risk for Alzheimer’s disease. Alzheimer’s disease is a complex neurodegenerative disease whose
genetic structure remains elusive, but this research provides convincing evidence that epistasis
plays an important role in disease etiology and must be thoroughly explored.
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